Key result
The pure orthosteric αIIbβ3 inhibitors Hr10 and modified tirofiban effectively prevented vascular thrombosis in humanized mice without causing the serious bleeding associated with partial agonist drugs.
Why the study?
Direct proof was lacking that bleeding complications from αIIbβ3 antagonism stem from drug-induced activating conformational changes, supporting the prevailing dogma that antithrombotic efficacy cannot be achieved without compromising hemostasis.
Do pure orthosteric inhibitors of αIIbβ3 prevent thrombosis without causing bleeding compared to partial agonists in preclinical models?
Population
Humanized mice and human platelets
Comparison
Hr10 and modified tirofiban vs partial agonist drugs
Design
Preclinical laboratory and animal study
Authors
Loading...
May warrant human trials of safer αIIbβ3 inhibitors; leaves open clinical translation beyond humanized mouse models.
Do pure orthosteric inhibitors of αIIbβ3 prevent thrombosis without causing bleeding compared to partial agonists in preclinical models?
Pure orthosteric inhibitors of αIIbβ3 prevent thrombosis while preserving hemostasis in preclinical models, suggesting a safer alternative to current partial agonist anti-platelet drugs.
Adair et al. (2020) studied Thrombosis. Hr10 and M-tirofiban vs. Eptifibatide, tirofiban, or PBS was evaluated on Bleeding volume and thrombus formation. The pure orthosteric αIIbβ3 inhibitors Hr10 and modified tirofiban effectively prevented vascular thrombosis in humanized mice without causing the serious bleeding associated with partial agonist drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: